Evaluation of clinical and inflammatory markers of nonalcoholic fatty liver disease in postmenopausal women with metabolic syndrome

Metabolic Syndrome and Related Disorders

Volumn 12, Issue 6, 2014, Pages 330-338

  Rodrigues, Marcio Hipolito ^a,b   Bruno, Anderson Souza ^a   Nahas Neto, Jorge ^a   Sandrim, Valeria C ^c   Muniz, Ludmila G ^c   Nahas, Eliana Aguiar Pet ^a  

^a SÃO PAULO STATE UNIVERSITY UNESP   (Brazil)

^b FEDERAL UNIVERSITY OF OURO PRETO   (Brazil)

^c Institute for Research and Teaching of Santa Casa de Misericordia of Belo Horizonte   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; BIOLOGICAL MARKER; GLUCOSE; INTERLEUKIN 6; TUMOR NECROSIS FACTOR;

ABDOMINAL OBESITY; ADULT; ARTICLE; CROSS-SECTIONAL STUDY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; POSTMENOPAUSE; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; WAIST CIRCUMFERENCE; ADVERSE EFFECTS; AGED; ANTHROPOMETRY; BLOOD; COMPLICATION; INFLAMMATION; MIDDLE AGED; MOTOR ACTIVITY; SMOKING;

ADIPONECTIN; AGED; ANTHROPOMETRY; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INFLAMMATION; INSULIN RESISTANCE; METABOLIC SYNDROME X; MIDDLE AGED; MOTOR ACTIVITY; NON-ALCOHOLIC FATTY LIVER DISEASE; POSTMENOPAUSE; SMOKING;

EID: 84904815632     PISSN: 15404196     EISSN: 15578518     Source Type: Journal    
DOI: 10.1089/met.2013.0140     Document Type: Article

References (39)

1. Clark JM. The epiDemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol 2006;40: S5-S10
2. Polyzos SA, Kountouras J, Zavos C, et al. The role of adiponectin in the pathogenesis and treatment of nonalcoholic fatty liver disease. Diabetes Obes Metab 2010;12: 365-383
3. Torres DM, Williams CD, Harrison SA. Features, diagnosis, and treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2012;10: 837-858
4. Loria P, Adinolfi LE, Bellentani S, et al. Practice guiDelines for the diagnosis and management of nonalcoholic fatty liver disease. A Decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee. Dig Liver Dis 2010;42: 272-282
5. Suzuki A, AbDemalek F. Nonalcoholic fatty liver disease in women. Women's Health 2009;5: 1-13
6. Lee CG, Carr MC, Murdoch SJ, et al. Adipokines, inflammation, and visceral adiposity across the menopausal transition: A prospective study. J Clin Endocrinol Metab 2009;94: 1104-1110
7. Hamaguchi M, Kojima T, Ohbora A, et al. Aging is a risk factor of non alcoholic fatty liver disease in premenopausalwomen. WorldJGastroenterol2012;18: 237-243
8. Caballeria L, Pera G, Rodriguez L, et al. Metabolic syndrome and nonalcoholic fatty liver disease in a Spanish population: Influence of the diagnostic criteria used. Eur J Gastroenterol Hepatol 2012;24: 1007-1011
9. Caballería L, AulaDell MA, Torán P, et al. Risk factors associated with non-Alcoholic fatty liver disease in subjects from primary care units. A case-control study. BMC Gastroenterol 2008;8: 44-50
10. Ford ES, Giles WH, Mokad AH. Increasing prevalence of the metabolic syndrome among US adults. Diabetes Care 2004; 27: 2444-2449
11. Nahas EAP, Padoani NP, Nahas-Neto J, et al. Metabolic syndrome and its associated risk factors in Brazilian postmenopausal women. Climacteric 2009;12: 431-438
12. Jou-Wei L, Caffrey JL, Chang MH, et al. Sex, menopause, metabolic syndrome, and all-cause and cause-specific mortality-cohort analysis from the third national health and nutrition examination survey. J Clin Endocrin Metab 2010;95: 4258-4267
13. McCullough AJ. Pathophysiology of nonalcoholic steatohepatitis. J Clin Gastroenterol 2006;40: S17-S29
14. Hijona E, Hijona L, Arenas JI, et al. Inflammatory mediators of hepatic steatosis. Mediators Inflamm 2010;2010: 837419
15. Bugianesi E, McCullough AJ, Marchesini G. Insulin resistance: A metabolic pathway to chronic liver disease. Hepatol 2005;42: 987-1000
16. Kirk EP, Klein S. Pathogenesis and pathophysiology of the cardiometabolic syndrome. J Clin Hypertens (Greenwich) 2009;11: 761-765
17. Petta S, Muratore C, Craxì A. Non-Alcoholic fatty liver disease pathogenesis: The present and the future. Dig Liver Dis 2009;41: 615-625
18. Rector RS, Thyfault JP, Wei Y, et al. Non-Alcoholic fatty liver disease and the metabolic syndrome: An update. World J Gastroenterol 2008;14: 185-192
19. Chen ZW, Chen LY, Dai HL, et al. Relationship between alanine aminotrasnferase levels and metabolic syndrome in nonalcoholic fatty liver disease. J Zhejiang Univ Sci B 2008;9: 616-622
20. Gutierrez-Grobe Y, Ponciano-Rodriguez G, Ramos MH, et al. Prevalence of non alcoholic fatty liver disease in premenopausal, postmenopausal and policistic ovary syndrome women: The role of estrogen. Ann Hepatol 2010;9: 402-409
21. Lemoine M, Ratziu V, Kim M, et al. Serum adipokine levels predictive of liver injury in non-Alcoholic fatty liver disease. Liver Int 2009;29: 1431-1438
22. NCEP Expert Panel on the Detection, evaluation, and treatment of high blood pressure in adults. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP). Adult Treatment Panel III (ATP III). JAMA 2001;285: 2444-2449
23. Geloneze B, Repetto EM, Geloneze SR, et al. The threshold value for insulin resistance (HOMA-IR) in an admixture population IR in the Brazilian Metabolic Syndrome Study. Diabetes Res Clin Pract 2006;72: 219-220
24. Tchelepi H, Ralls PW, Radin R, et al. Sonography of diffuse liver disease. J Ultrasound Med 2002;21: 1023-1032
25. Mayes JS, Watson GH. Direct effects of sex steroid hormones on adipose tissues and obesity. Obes Rev 2004;5: 197-216
26. Ratziu V, Bellentanib S, Cortez-Pinto H, et al. A position statement on NAFLD/NASH based on the EASL 2009 Special Conference. J Hepatol 2010;53: 372-384
27. Marchesini G, Bugianesi E, Forlani G, et al. Nonalcoholic fatty liver, steatohepatitis and the metabolic syndrome. Hepatology 2003;37: 917-923
28. Wong VW, Chu WC, Wong GL, et al. Prevalence of nonalcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: A population study using proton-magnetic resonance spectroscopy and transient elastography. Gut 2012;61: 409-415
29. Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: From steatosis to cirrhosis. Hepatology 2006;43: S99-S112
30. Pittas AG, Joseph NA, Greenberg AS. Adipocytokines and insulin resistance. JClin EndocrinolMetab 2004; 89: 447-452
31. Jarrar MH, Baranova A, Collantes R, et al. Adipokines and cytokines in non-Alcoholic fatty liver disease. Aliment Pharmacol Ther 2008;27: 412-421
32. Bajaj M, Suraamornkul S, Piper P, et al. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazonetreated type 2 diabetic patients. J Clin Endocrinol Metab 2004;89: 200-206
33. Turer AT, Browning JD, Ayers CR, et al. Adiponectin as an inDepenDent predictor of the presence and Degree of hepatic steatosis in the Dallas Heart Study. J Clin Endocrinol Metab 2012;97: E982-E986
34. Aygun C, Senturk O, Hulagu S, et al. Serum levels of hepatoprotective peptiDe adiponectin in non-Alcoholic fatty liver disease. Eur J Gastroenterol Hepatol 2006;18: 175-180
35. Polyzos SA, Toulis KA, Goulis DG, et al. Serum total adiponectin in nonalcoholic fatty liver disease: A systematic review and meta-Analysis. Metabolism 2011;60: 313-326
36. Strauss S, Gavish E, Gottlieb P, et al. Interobserver and intraobserver variability in the sonographic assessment of fatty liver. Am J Roentgenol 2007;189: W320-W322
37. Hernaez R, Lazo M, Bonekamp S, et al. Diagnostic accuracy and reliability of ultrasonography for the Detection of fatty liver: A meta-Analysis. Hepatology 2011;54: 1082-1090
38. AGA (American Gastroenterological Association). American Gastroenterological Association Medical Position Statement: Nonalcoholic fatty liver disease. Gastroenterology 2002;123: 1702-1704
39. IBGE. POF (Pesquisa De Orçamentos Familiares) 2008-2009. Available at www.ibge.gov.br/home/presiDencia/noticias. Accessed October, 2012.